Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press21810.17650/1726-9776-2011-7-4-37-41DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряREPEAT TRANSURETHRAL RESECTION OF THE BLADDER AND THE RESULTS OF TREATMENT IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCERПОВТОРНАЯ ТРАНСУРЕТРАЛЬНАЯ РЕЗЕКЦИЯ МОЧЕВОГО ПУЗЫРЯ И РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯSemenovA. V.СеменовА. В.
Russian Federation
andrey.semenov@mail.ruKosulinaA. A.КосулинаА. А.
Russian Federation
andrey.semenov@mail.ruDepartment of Oncology, Radiotherapy, and Radiodiagnosis, Ivanovo State Medical Academy, Ministry of Health and Social Development of RussiaКафедра онкологии, лучевой терапии и лучевой диагностики ГОУ ВПО Ивановская ГМА Минздравсоцразвития России301220117437410108201401082014https://oncourology.abvpress.ru/oncur/article/view/218

A comprehensive analysis was made to study whether it was expedient to use repeat transurethral resection (TUR) of the bladder to treat patients with non-muscle invasive bladder cancer (NMIBC) in routine practice, by clarifying the impact of repeat TUR of the bladder on relapse-free survival time and estimating the prognostic value of this procedure. A prospective study enrolled 2 groups of patients with NMIBC (Т1NxM0 G1 3) made up according to the scope of surgical treatment (single and repeat TUR of the bladder) with a median follow-up of 26 months. The therapeutic effect of TUR carried out 4-6 weeks after primary TUR was noted only in patients at low and moderate risk for recurrence. The possibilities of using repeat TUR are also shown to predict risk for early recurrence and to choose the optimal surgical policy for patients with NMIBC, which make it possible to recommend its incorporation into routine clinical practice.

Проведен комплексный анализ целесообразности применения повторной трансуретральной резекции (ТУР) мочевого пузыря (МП) в рутинной практике лечения больных немышечно-инвазивным раком мочевого пузыря (НМИ РМП) на основании уточнения влияния повторной ТУР МП на время безрецидивной выживаемости и оценки прогностического значения данной методики. В проспективное исследование были включены 2 группы больных НМИ РМП (Т1N×M0 G1–3 ), сформированные в зависимости от объема проведенного им хирургического лечения (однократная и повторная ТУР МП) при медиане наблюдения 26 мес. Терапевтический эффект ТУР МП, проведенной через 4−6 нед после первичной, был отмечен только для пациентов групп низкого и среднего риска рецидивирования. Также были продемонстрированы возможности использования повторной ТУР для прогнозирования риска раннего рецидива и выбора оптимальной хирургической тактики лучения больных НМИ РМП, позволяющие рекомендовать ее введение в рутинную клиническую практику.

non-muscle invasive bladder cancerrepeat transurethral resection of the bladderrelapse-free survivalrestagingrisk for recurrenceнемышечно-инвазивный рак мочевого пузыряповторная трансуретральная резекция мочевого пузырябезрецидивная выживаемостьрестадированиериск рецидивирования1. Oosterlinck W., Lobel B., Jakse G. et al. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41(2):105−12.Oosterlinck W., Lobel B., Jakse G. et al. European Association of Urology (EAU) Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 2002;41(2):105−12.2. Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3):466−77.Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3):466−77.3. Brausi M., Collette L., Kurth K. et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523−31.Brausi M., Collette L., Kurth K. et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523−31.4. Jahnson S., Wiklund F., Duchek M. et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 2005;39(3):206−10.Jahnson S., Wiklund F., Duchek M. et al. Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol 2005;39(3):206−10.5. Witjes J.A., Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 2007;4:542–9.Witjes J.A., Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 2007;4:542–9.6. Divrik T., Yildirim U., Eroglu A.S. et al. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006; 175:1258–61.Divrik T., Yildirim U., Eroglu A.S. et al. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 2006; 175:1258–61.7. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162:74–6.Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999; 162:74–6.8. Brauers A., Buettner R., Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165(3):808–10.Brauers A., Buettner R., Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165(3):808–10.9. Schips L., Augustin H., Zigeuner R.E. et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59(2):220–3.Schips L., Augustin H., Zigeuner R.E. et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59(2):220–3.10. Grimm M.-O., Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170(2 Pt 1):433–7.Grimm M.-O., Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170(2 Pt 1):433–7.11. Herr H.W., Donat M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97:1194−8.Herr H.W., Donat M. A re-staging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006; 97:1194−8.